Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FRNA-211
- Development stage
- Preclinical
- Lead developer
- TRIZ Biopharma Innovations
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
FRNA-211 is a preclinical anticancer drug candidate being developed by TRIZ Biopharma Innovations. It is described as a self-organizing "quasi-living system" based on modified RNA with microRNA-like properties. The drug is designed to exert a cytostatic effect, inhibiting the growth and proliferation of cancer cells rather than necessarily killing them directly. FRNA-211 has demonstrated significant activity in more than 50 cell cultures and in three distinct animal models. It represents part of the company's innovative approach to developing dynamic, self-adaptive therapeutics aimed at treating various forms of cancer.
Beyond the preview
Go deeper on FRNA-211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FRNA-211.